HomeHealthcare & Life SciencesPharmaceuticals Myasthenia Gravis Treatment Market

North America Myasthenia Gravis Treatment Market Size & Outlook, 2025-2033


North America Myasthenia Gravis Treatment Market Insights

  • Based on Reed Intelligence findings, the North America Myasthenia Gravis Treatment Market size reached USD 827.55 Million in 2024 and is expected to grow to USD 1947.21 Million by 2033.
  • During 2026–2033, the market is forecasted to advance at a CAGR of 10.01%.
  • Ocular MG  represented the largest share of the By Type market in terms of size in 2024.
  • Among the By Type segments, Transient Neonatal MG is forecasted to achieve the highest growth and remain the most lucrative through the forecast period.

Other Key Findings


  • In 2024, North America accounted for 39.22% of the global Myasthenia Gravis Treatment Market size.
  • By 2033, United States is projected to lead the global market in terms of market size.
  • United States is projected to emerge as the fastest-growing market in North America, reaching USD 1542.36 Million by 2033.

Report Summary

Report Scope Details
Base Year for Study 2024
Study Period 2021-2033
Historical Period 2021-2023
Forecast Period 2025-2033
Market Size In 2024 USD 827.55 Million
Market Size In 2033 USD 1947.21 Million
Largest segment Ocular MG 
Units Revenue in USD Million
CAGR 10.01% (2025-2033)
Segmnetation Covered
North America
  1. United States
  2. Canada
By Type
  1. Ocular MG 
  2. Congenital MG 
  3. Transient Neonatal MG
By Treatment
  1. Medication 
  2. Surgery 
  3. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
  4. Plasmapheresis and Intravenous Immunoglobulin 
  5. Others
By End-User
  1. Hospitals 
  2. Clinics 
  3. Academic Research Institutes 
  4. Others
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Related Reports